Taking its TOLL: the role of toll-like receptor 4 in human health and disease, and its potential as a therapeutic target.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic biology and previous clinical trial findings without primary human data or systematic review methodology.
PubMed 41869302 · doi:10.3389/fimmu.2026.1761361
What was done
This narrative review synthesized literature on Toll-like receptor 4 (TLR4) signaling, its role in host defense and inflammatory disease pathogenesis across multiple organ systems, and outcomes of TLR4-targeted therapeutic candidates in clinical trials.
What was found
The abstract reports no numbers or statistical values. TLR4 activation by PAMPs and DAMPs triggers pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and type 1 interferons (IFN-α, IFN-β). TLR4 provides host defense against Gram-negative bacteria via lipopolysaccharide recognition, but excessive activation contributes to central nervous system, cardiovascular, respiratory, and metabolic pathology. Targeted therapeutics including Eritoran and TAK-242 failed to demonstrate clinical efficacy in human trials.
Why it matters
The review highlights the dual, context-dependent nature of TLR4 signaling, providing context for why targeted inhibition has struggled translationally despite strong preclinical evidence.
Limits
The abstract describes a broad narrative synthesis without original empirical data, sample sizes, quantitative effect estimates, or systematic review methodology.
Cited by
- supports Toll-like receptors on innate immune cells recognize specific patterns such as gut bacterial lipopolysaccharides.